Dawaa Reference

Clinical reference

Lichen sclerosus

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources1 source

British Society for the Study of Vulval Disease / British Association of Dermatologists guidance on the management of lichen sclerosus (clobetasol propionate tapering regimen)

Verified against2 documents
  • British Society for the Study of Vulval Disease / British Association of Dermatologists guidance on the management of lichen sclerosus (clobetasol propionate tapering regimen)
  • Lichen Sclerosus - disease-level clinical article (lichen-sclerosus-clinical.txt)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (7)

  • The main complaint is itching, which typically worsens after dark [itching]
  • Marked itch, local burning, pain, and painful bowel movements are common complaints [burning pain · itching]
  • Constipation is common in affected children but uncommon in affected adults [constipation]
  • Some lesions cause no symptoms at all
  • Girls often present with vulval irritation and soreness, which can be mistaken for sexual abuse
  • Red flag: the lesions can go on to destroy anatomical structures and impair function, and they carry a risk of turning malignant - which is why treatment and long-term follow-up are not optional
  • It can cause phimosis in a man, or scarring of the entrance to the vagina in a woman [scarring]

Signs — what you find (10)

  • Early lesions are sharply outlined redness that evolves into thin, pale ivory or porcelain-like sclerotic plaques [pallor · plaques · redness]
  • Repeated scratching can thicken the plaques over time [itching · plaques]
  • Dilated small vessels, purpura, cracks, ulcers, and swelling can also be seen [purpura · rash]
  • Genital disease starts around the clitoral hood and can spread into a figure-of-eight pattern over the vulva, perineum, and anus - the keyhole sign
  • The vagina and cervix are usually spared
  • New lesions can appear at sites of trauma (the Koebner phenomenon), and abuse can worsen existing lesions [skin lesions]
  • In males, disease affects the foreskin, glans, and the groove behind the glans
  • Skin patches away from the genitals are usually symptomless and favour the area under the breasts, the neck, wrists, thighs, upper back, and shoulders
  • Oral involvement looks like bluish-white bumps on the inner cheek or under the tongue
  • It is a mucocutaneous autoimmune disorder whose marks are loss of pigment and thinning of the skin; it lands on genital skin most often and elsewhere less, and on women more than men [pigmentation change]

Tests (4)

  • Diagnosis is usually made clinically, with biopsy reserved for select cases
  • Biopsy is reserved for an atypical presentation, suspected cancer, or failure to respond to first-line treatment
  • An abnormal biopsy result does not exclude the diagnosis
  • Thyroid function should be checked, with further autoimmune work-up guided by symptoms

If not this — what else fits (8)

  • Child sexual abuse is a mimic, though the two conditions can coexist
  • Lichen planus
  • Lichen simplex chronicus
  • Vitiligo
  • Morphea (localized scleroderma)
  • Eczema (atopic dermatitis)
  • Contact dermatitis
  • Psoriasis

SourceStatPearls "Lichen Sclerosus" - disease-level clinical article

Presentation findings are traced to the source above.

1

CLOBETASOL PROPIONATE

1st line

Formtopical

Adult dose and duration

Apply one fingertip unit (0.5 g) of 0.05% ointment once at night for 4 weeks, then on alternate nights for 4 weeks, then twice weekly for 4 weeks. A 30 g tube should last the whole 12 weeks. - A 12-week reducing course, then twice-weekly or as-needed maintenance; aim for no more than 30-60 g in a year

Paediatric dose

It does occur in girls before puberty, presenting as itch, soreness, constipation or apparent bleeding that is sometimes mistaken for abuse. The same potent steroid is used, but under specialist supervision - refer rather than starting it.

Dose source

British Society for the Study of Vulval Disease / British Association of Dermatologists guidance on the management of lichen sclerosus (clobetasol propionate tapering regimen)

Why

Lichen sclerosus is not simply an itch. Left undertreated it scars - the clitoris becomes buried, the labia fuse, the introitus narrows - and it carries a small risk of vulval squamous cell carcinoma. A potent topical steroid prevents that. Using a weak steroid because the site is delicate is the common and damaging mistake.

Cautions
  • A persistent sore, ulcer, lump or thickened area lasting more than about 4 weeks needs urgent referral on a 2-week cancer pathway. Lichen sclerosus carries a small risk of vulval squamous cell carcinoma.
  • Review at 3 months and again at 9 months. Aim for 30-60 g of clobetasol a year; needing much more means the diagnosis or the adherence needs rechecking.
  • A fingertip unit is the amount squeezed along the last joint of an adult index finger, roughly 0.5 g. Being exact about this is what prevents both undertreatment and steroid thinning.
  • Do not keep treating it as thrush. Recurrent vulval itch that does not respond to antifungals is lichen sclerosus until proved otherwise.
  • An emollient used as a soap substitute alongside; no soap, bubble bath, wipes or perfumed products on the area.
  • It occurs in men as balanitis xerotica obliterans. Phimosis from it needs urology, and circumcision can be curative.
  • This is a lifelong condition that relapses. Tell the patient that at the start, or the first flare will be read as failure.
Egyptian brands
Egyptian brandManufacturerIndicative price
CLOBITAT 0.05% TOPICAL CREAM 15 GMBIORIGINAL INTERNATIONAL GROUP PHARMA EGYPT5.50 EGP
DERMASOL 0.05% CREAM 20 GMUP PHARMA5.50 EGP
DERMASOL 0.05% OINT. 20 GMUP PHARMA5.50 EGP
CLEROVATE 0.05% TOPICAL OINT. 25 GMMARCYRL PHARMACEUTICAL INDUSTRIES (MPI)7.50 EGP
CLOVACORT 0.05% GEL 20 GMEUROPEAN EGYPTIAN PHARM. IND.9.00 EGP
CLEROVATE 0.05% CREAM 25 GMMARCYRL PHARMACEUTICAL INDUSTRIES (MPI)10.25 EGP
DERMOVATE 0.05 % OINTMENT 25 GMGLAXO SMITHKLINE44.00 EGP
DERMOVATE 0.05% TOP. CREAM 25 GMGLAXO SMITHKLINE44.00 EGP
2

REFERRAL & SAFETY-NETTING (NO DRUG THERAPY)

1st line
Dose source

Lichen Sclerosus - disease-level clinical article (lichen-sclerosus-clinical.txt)

Why

Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.

Cautions
  • RED FLAG - There is a risk of malignant transformation to squamous cell carcinoma, requiring long-term follow-up.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.